IP Library › Granted Patent US 10,220,063
Granted Patent B2
US 10,220,063 · App. 16/056,726 · Granted Mar 5, 2019

Compositions and methods for enhancing sexual pleasure and performance

Inventor: Dennis M. Jenn (South Jordan, UT)
A61K36/185A21D2/14A23C15/12A23L29/35A61K9/007A61K9/0034A61K31/05A61K31/352A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,220,063
App. No.
16/056,726
Granted
Mar 5, 2019
Kind
B2
Abstract

Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis , including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis , and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.

Claims (29)

1. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:

a cannabinoid component consisting essentially of about 10 mg to about 500 mg of tetrahydrocannabinol and about 10 mg to about 500 mg of cannabidiol; and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

2. The tablet or capsule of claim 1 , wherein the cannabinoid component contains at least one of cannabinol, tetrahydrocannabivarin, cannabigerol, dronabinol, nabilone, and mixtures thereof.

3. The tablet or capsule of claim 1 , wherein at least a portion of the cannabinoid component is obtained from plant parts of one or more plants selected from Cannabis sativa, Cannabis indica , and hybrids thereof.

4. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 400 mg of tetrahydrocannabinol.

5. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 300 mg of tetrahydrocannabinol.

6. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 250 mg of tetrahydrocannabinol.

7. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 400 mg of cannabidiol.

8. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 300 mg of cannabidiol.

9. The tablet or capsule of claim 1 , wherein the tablet or capsule contains about 10 mg to about 250 mg of cannabidiol.

10. The tablet or capsule of claim 1 , wherein the tablet or capsule is ingestible.

11. The tablet or capsule of claim 1 , wherein the tablet or capsule is a suppository.

12. The tablet or capsule of claim 1 , wherein the sexual response enhancing component is sildenafil or tadalafil.

13. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:

a cannabinoid component consisting essentially of about 10 mg to about 400 mg of tetrahydrocannabinol and about 10 mg to about 400 mg of cannabidiol; and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

14. The tablet or capsule of claim 13 , wherein the tablet or capsule further consists essentially of a supplement selected from the group consisting of L-arginine, yahimbe root, ginseng, gingko biloba , and horny goat weed.

15. The tablet or capsule of claim 13 , wherein the tablet or capsule is ingestible.

16. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:

a cannabinoid component consisting essentially of about 10 mg to about 300 mg of tetrahydrocannabinol and about 10 mg to about 300 mg of cannabidiol;

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil; and

at least one supplement selected from the group consisting of L-arginine, yahimbe root, ginseng, gingko biloba , and horny goat weed.

17. The tablet or capsule of claim 16 , wherein the tablet or capsule is ingestible.

18. A tablet or capsule for enhancing sexual response and sensitivity in a human, consisting essentially of:

a cannabinoid component consisting essentially of about 10 mg to about 250 mg of tetrahydrocannabinol and about 10 mg to about 250 mg of cannabidiol; and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

19. The tablet or capsule of claim 18 , wherein the tablet or capsule further consists essentially of a supplement selected from the group consisting of L-arginine, yahimbe root, ginseng, ginkgo biloba , and horny goat weed.

20. The tablet or capsule of claim 18 , wherein the cannabinoid component contains at least one of cannabinol, tetrahydrocannabivarin, cannabigerol, dronabinol, nabilone, and mixtures thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2021
From: ILYSM, LLC
To: ILYLT, LLC
Reel/Frame 055062/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: JENN, DENNIS M
To: ILYSM, LLC
Reel/Frame 046569/0917 →
Continuity (3)
Continuation In Part 14538527 · Nov 11, 2014
Provisional Application 61902501 · Nov 11, 2013
Related Publication 20180360896A1 · Dec 20, 2018